January 26, 2018 – Toronto, Ontario – Matica Enterprises Inc. (MMJ–CSE) (39N – Frankfurt) (MQPXF – OTC PINK) (“Matica” or the “Company”) announces that in response to Health Canada’s January 25, 2018 changes to the physical security requirements under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), the Company is conducting a review of the required Confirmation of Readiness submission for its Dorval, Quebec facility. The Company will be evaluating the existing security system and making any adjustments necessary to ensure that the facility meets Health Canada’s revised requirements.
Management had previously announced an expected January 26th completion date of the Dorval facility (NR December 27, 2017). Matica and RoyalMax Biotechnology Canada Inc. (“RoyalMax”) management do not anticipate any undue delays as the Dorval facility has been built to exceed Health Canada requirements. Once any adjustments to the facility are completed, management will be submitting the Photographic-Evidence video to Health Canada to request a cultivation license.
For more information on Matica please visit the website at: www.maticaenterprises.com.
On behalf of the Board of Directors
MATICA ENTERPRISES INC.
Boris Ziger, CEO & Chairman
For further information, please contact Boris Ziger, Chief Executive Officer, at:
Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.
The CSE has not reviewed, approved or disapproved the content of this press release.